Inactive Instrument

Growblox Sciences Inc Stock Other OTC

Equities

US3998471029

Biotechnology & Medical Research

End-of-day quote Other OTC
- USD - Intraday chart for Growblox Sciences Inc
Sales 2022 - Sales 2023 - Capitalization 6.83M
Net income 2022 - Net income 2023 -4M EV / Sales 2022 -
Net Debt 2022 1.15M Net Debt 2023 1.29M EV / Sales 2023 -
P/E ratio 2022
-16.8 x
P/E ratio 2023
-1.56 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 87.78%
More Fundamentals * Assessed data
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
GB Sciences, Inc. Auditor Raises 'Going Concern' Doubt CI
Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of Lethbridge CI
GB Sciences, Inc. announced a financing transaction CI
GB Sciences, Inc. Announces Executive Changes CI
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Gb Sciences, Inc. Receives Positive Preclinical Results in an Interim Report from Its Study Using Preclinical Zebrafish Models of Stress At the National Research Council of Canada CI
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022 CI
GB Sciences, Inc. Auditor Raises 'Going Concern' Doubt CI
GB Sciences, Inc. announced a financing transaction CI
More news
Managers TitleAgeSince
Chief Executive Officer 76 15-07-26
President 54 14-06-09
Corporate Officer/Principal - 18-08-31
Members of the board TitleAgeSince
President 54 14-06-09
Chief Executive Officer 76 15-07-26
More insiders
GB Sciences, Inc. is a biopharmaceutical research and development company. The Company develops disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned subsidiary, GbS Global Biopharma, Inc. (GBSGB). The Company's primary focus is on preparing its lead program for the treatment of the motor symptoms of Parkinson's disease (PD) in a human clinical trial. Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB has a portfolio of intellectual property containing both plant-inspired formulations and its artificial intelligence (AI)-enabled drug discovery platform, as well as research contracts and various supplier arrangements. GBSGBs intellectual property covers a range of over 65 medical conditions, from which five drug development programs are in the preclinical stage of drug development.
More about the company